文献速递外周动脉疾病血液透析通路

外周血管腔内手术入路部位并发症的前瞻性注册研究:预测因素与后果

Access Site Complications of Peripheral Endovascular Procedures: A Large, Prospective Registry on Predictors and Consequences.
PubMed 文献 · J Endovasc Ther · 2021-06-17

该前瞻性观察研究连续纳入单中心5263例受试者的5385例外周血管腔内诊疗操作,评估术后第1天急性入路部位并发症(ASCs)的预测因素与后果。ASCs发生率为16.6%,独立预测因素包括高龄、女性、溶栓、围术期肝素、穿刺时间、鞘管尺寸、肱动脉入路及单纯压迫止血;20.2%的ASCs需治疗,17.7%延长住院,3例死于入路相关出血。

要点

  • 外周血管腔内术后第1天ASCs发生率为16.6%,以血肿为主(78.6%)。
  • 独立预测因素包括高龄、女性、溶栓、围术期肝素、鞘管尺寸大、肱动脉入路及未用闭合装置。
  • 20.2%的ASCs需治疗,17.7%延长住院,3例死亡与入路出血相关。

核心结论

  • 外周血管腔内手术后ASCs与高龄、女性、围术期抗血栓药物、肱动脉入路、术后出血及未使用血管闭合装置相关。

研究设计与样本

  • 前瞻性观察性研究,单中心连续纳入5263例受试者共5385例外周血管腔内诊断或介入操作。

主要发现

  • ASCs发生于16.6%的外周血管腔内操作,其中血肿占78.6%、假性动脉瘤占18.9%、动静脉瘘占1.4%、明显出血占1.1%。
  • 独立预测因素:年龄每增加10岁OR 1.12(p=0.004);男性OR 0.77(p=0.001);溶栓OR 3.56(p<0.001);肝素5000 IU OR 1.96(p=0.001)、>5000 IU OR 3.56(p=0.02);穿刺时间每10秒OR 1.01(p<0.001);鞘管尺寸每French OR 1.59(p<0.001);肱动脉入路对比逆行股动脉OR 4.58(p<0.001);单纯压迫对比Angio-Seal OR 0.57(p=0.02)、对比ProGlide OR 0.36(p<0.001)、对比FemoSeal OR 0.57(p<0.001)。
  • 20.2%的ASCs需要治疗,17.7%导致住院时间延长,3例受试者死于入路部位相关出血。

临床怎么用

  • 对于高龄、女性、使用溶栓或围术期肝素、需较大鞘管或肱动脉入路的患者,应加强入路部位并发症防范。
  • 优先考虑使用血管闭合装置(Angio-Seal、ProGlide或FemoSeal)以降低ASCs风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to investigate predictors and consequences of acute vascular access site complications (ASCs) related to peripheral endovascular diagnostic or interventional procedures. Despite improvement of puncture techniques, access site-related morbidity and mortality is still considerable. MATERIALS AND METHODS: A total of 5263 participants who underwent 5385 endovascular procedures at a single center were consecutively included in this prospective, observational study. Primary outcomes were ASCs defined as composite of puncture site hematoma, pseudoaneurysm, arteriovenous fistula, and overt puncture site bleeding on the first day after procedure. RESULTS: ASCs occurred in 16.6% of peripheral endovascular procedures (78.6% hematomas, 18.9% pseudoaneurysms, 1.4% arteriovenous fistulas, 1.1% overt bleedings). Independent predictors were advanced age [odds ratio (OR) per 10 years: 1.12, p=0.004], female sex (OR men, 0.77; p=0.001), lysis (OR 3.56; p<0.001), periprocedural heparin (OR 5000 IU, 1.96; p=0.001; OR >5000 IU, 3.56; p=0.02), time to access (OR per 10 seconds, 1.01; p<0.001), sheath size (OR per French, 1.59; p<0.001), brachial artery access (OR vs retrograde transfemoral, 4.58; p<0.001), and compression only (OR Angio-Seal, 0.57, p=0.02; ProGlide, 0.36, p<0.001; FemoSeal, 0.57, p<0.001). Treatment was required in 20.2% and prolonged hospitalization in 17.7% of ASC. Three participants died from access site-related bleeding. CONCLUSION: ASCs after peripheral endovascular procedures are associated with advanced age, female sex, periprocedural antithrombotic medication, brachial artery access, postinterventional bleeding, and nonuse of vascular closure devices.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Ciprian Cacuci A, Krankenberg H, Ingwersen M, et al. Access Site Complications of Peripheral Endovascular Procedures: A Large, Prospective Registry on Predictors and Consequences. J Endovasc Ther. 2021. PMID: 34137662. doi:10.1177/15266028211025044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。